Warning: The NCBI web site requires JavaScript to function. more...
Role of RANKL inhibition in osteoporosis.
McClung M.
Arthritis Res Ther. 2007;9 Suppl 1:S3. Review.
Related citations
Inhibition of RANK/RANKL signal transduction pathway: a promising approach for osteoporosis treatment.
Bai YD, Yang FS, Xuan K, Bai YX, Wu BL.
Med Hypotheses. 2008 Aug;71(2):256-8. Epub 2008 Apr 28.
[The role of rank-ligand inhibition in the treatment of postmenopausal osteoporosis].
Varenna M, Gatti D.
Reumatismo. 2010 Jul-Sep;62(3):163-71. Review. Italian.
RANK ligand inhibition with denosumab for the management of osteoporosis.
Lewiecki EM.
Expert Opin Biol Ther. 2006 Oct;6(10):1041-50. Review.
Inhibition of RANKL as a treatment for osteoporosis: preclinical and early clinical studies.
McClung MR.
Curr Osteoporos Rep. 2006 Mar;4(1):28-33. Review.
Clinical potential of RANKL inhibition for the management of postmenopausal osteoporosis and other metabolic bone diseases.
Delmas PD.
J Clin Densitom. 2008 Apr-Jun;11(2):325-38. Epub 2008 Apr 2. Review.
Treatment of osteoporosis with denosumab.
Maturitas. 2010 Jun;66(2):182-6. Epub 2010 Mar 16. Review.
RANKL inhibition in the treatment of bone metastases.
Lipton A, Jun S.
Curr Opin Support Palliat Care. 2008 Sep;2(3):197-203. Review.
Denosumab: anti-RANKL antibody.
Miller PD.
Curr Osteoporos Rep. 2009 Mar;7(1):18-22. Review.
Targeting the RANK/RANKL/OPG signaling pathway: a novel approach in the management of osteoporosis.
Hamdy NA.
Curr Opin Investig Drugs. 2007 Apr;8(4):299-303. Review.
Denosumab for the treatment of osteoporosis.
Iqbal J, Sun L, Zaidi M.
Curr Osteoporos Rep. 2010 Dec;8(4):163-7.
Clinical applications of RANK-ligand inhibition.
Romas E.
Intern Med J. 2009 Feb;39(2):110-6. Review.
Denosumab--an emerging treatment for postmenopausal osteoporosis.
Expert Opin Biol Ther. 2010 Mar;10(3):467-76. Review.
Denosumab: RANKL inhibition in the management of bone loss.
Drugs Today (Barc). 2008 Jan;44(1):7-21. Review.
CLINICAL Review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications.
Vega D, Maalouf NM, Sakhaee K.
J Clin Endocrinol Metab. 2007 Dec;92(12):4514-21. Epub 2007 Sep 25. Review.
Clinical development of anti-RANKL therapy.
Schwarz EM, Ritchlin CT.
Arthritis Res Ther. 2007;9 Suppl 1:S7. Review.
Denosumab update.
Curr Opin Rheumatol. 2009 Jul;21(4):369-73. Review.
Advances in bone biology and new treatments for bone loss.
Gallagher JC.
Maturitas. 2008 May 20;60(1):65-9. Epub 2008 Jun 13. Review.
[OPG/RANKL: role and therapeutic target in osteoporosis].
Marie P, Halbout P.
Med Sci (Paris). 2008 Jan;24(1):105-10. French.
[Denosumab. The first inhibitor of RANK-ligand for treatment of osteoporosis].
Bruhn C.
Med Monatsschr Pharm. 2010 Oct;33(10):370-5. Review. German.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on